ADPT
Adaptive Biotechnologies Corporation
Healthcare · Diagnostics & Research · NMS
$13.84
Close 2026-05-28
✓ ETHICAL PASS

UNKNOWN MOAT
HIGH
Data Confidence: 86%
Full financial profile available
Market Cap
$2.2B
Trailing P/E
Forward P/E
-53.82
Rev Growth
+35.1%
Profit Margin
-16.8%
ROE
-24.0%
Analyst Target
$20.00
Recommendation
STRONG BUY
About Adaptive Biotechnologies Corporation

Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunosequencing platform which combines a suite of proprietary chemistry, computational biology, and machine learning to generate clinical immunomics data to decode the adaptive immune system. It provides clonoSEQ diagnostic test which detects and monitors the remaining number of cancer cells that are present in a patient's body during and after treatment, known as Minimal Residual Disease (MRD). The company offers products and services for life sciences research, clinical diagnostics, and drug discovery applications. The company was formerly known as Adaptive TCR Corporation and changed its name to Adaptive Biotechnologies Corporation in December 2011. Adaptive Biotechnologies Corporation was incorporated in 2009 and is headquartered in Seattle, Washington.

Ethical Screen
Business ActivityPASS
Debt RatioN/A
Cash RatioN/A
Receivables RatioN/A
Revenue Ratio (0.00%)PASS
OverallPASS
Score Ethical: 64.7
Score Valuation: 33.0
Score Quality: 33.8
Score Combined: 37.8

Full Analysis

Opportunity scores, earnings history, insider transactions, institutional holders, analyst consensus, and more.

Unlock with Membership
Opportunity Scores
Valuation50.0
Quality25.0
Cash Flow9.1
Moat40.0
Balance Sheet0.0
Debt Purity50.0
Liquid Purity50.0
Rev Purity100.0
Compliance100.0
Tier: WATCH · Score: 38.2 · Rank: #4439
Insider Transactions
No insider transaction data.
Top Institutional Holders
No institutional holder data.
Additional Fundamentals
Enterprise Value
$2.4B
Price/Book
11.21
Beta
2.163
Analysts
7
Total Revenue (TTM)
$295.4M
Total Debt
$208.2M
Rec. Mean
1.50
Short Ratio
5.62
Short % Float
0.1%
Employees
624

Elite Intelligence

Trade Consideration with position sizing, convergence signals, and risk analysis. Available to Elite members.

Upgrade to Elite
Trade Consideration
The Opportunity
Score 37.8 (P39 — top 60.9% of scored tickers). Unknown Moat. Ethical PASS. 7 analysts at Strong Buy.
Price: $13.84 | Target: $20.14 (+46%)
Score
38
Moat
Unknown
Conviction
Standard
Upside
+46%
The Fundamentals
Revenue Growth+35.1%
Profit Margin-16.8%
ROE-24.0%
Forward P/E-53.8
Market Cap$2.2B
Position Sizing Scenarios
Stop: $11.76 (-15%) | Entry: $13.84
SharesCostProfit to TargetR:R
To Consensus ($20.14, 7 analysts)
10$138.40+$63.00 (46%)3.0R
50$692.00+$315.00 (46%)3.0R
100$1,384.00+$630.00 (46%)3.0R
Risk Factors
  • High beta (2.16) — amplifies market moves by 2.16x
  • Elevated short interest (5.62 days to cover)
The Verdict
Adaptive Biotechnologies Corporation passes all ethical screens, holds a unknown competitive moat, and is growing revenue at +35.1%.
Quantitative Grade

A single score combining all analytical layers below. A is strongest, D is weakest.

B
Quant Score
61.1
Risk Grade
Layers
7
Quality: HIGH_SORTINO
Risk Profile

How much could this ticker lose on a bad day? These metrics measure worst-case scenarios from historical data.

VaR 95%
-6.2%
worst expected daily loss, 19 in 20 days
CVaR 95%
-9.0%
avg loss on the worst 5% of days
Annual Volatility
Sortino Ratio
1.76
above 1.0 is good
Max Drawdown
-39.4%
Worst Day
Forward Outlook

Based on 10,000 simulated price paths, here is the probability of where this ticker could be in 30, 60, and 90 days.

30d Prob Up
90d Prob Up
Median Return 30d
Liquidity Score
80
Liquidity Grade
HIGHLY LIQUID
Trend & Momentum

What direction is this ticker actually moving, filtered through noise? Is it speeding up or slowing down?

Kalman Trend
Trend Strength
Momentum Signal
HMM Regime
RSI Signal
Technical Signals

Classic chart signals that institutional traders monitor. Golden Cross is bullish, Death Cross is bearish.

MA Crossover
DEATH_CROSS
Bollinger Position
ABOVE_UPPER
Beta
Relative Volume
0.9x
Short Interest
Financial Health

Is this company financially sound? The Z-Score measures bankruptcy risk. The F-Score measures fundamental strength.

Altman Z-Score
below 1.81 = distress zone
Piotroski F-Score
Earnings Beat Rate
Earnings Consistency
Correlations

These tickers tend to move together (positive) or in opposite directions (negative). Useful for portfolio diversification.

Most Correlated
TickerCorrelation
ARKG0.656
IWM0.482
TWST0.481
ARKK0.474
BEAM0.452
Inverse Correlated
TickerCorrelation
ED-0.159
BAES.L-0.156
KR-0.144
1724.KL-0.139
CBOE-0.138
Seasonality

Does this ticker have consistent patterns on certain days or months? Historical tendencies, not guarantees.

Best Day
Monday
Worst Day
Tuesday
Best Month
Jan
Worst Month
Mar
Fri-Mon Effect
-0.5118110140658126
Momentum Rankings

How does this ticker's recent performance compare to the entire universe? Ranked across 1, 3, 6, and 12-month returns.

1M Return
+8.2%
3M Return
-7.7%
6M Return
-25.8%
12M Return
+66.2%
Momentum Rank
#2374
Momentum Signal
FLAT

Get our daily market read free. Join thousands of traders.

Free Explorer Access